Program
XTMAB-16
A development code. Also written as “XTMAB-16 2 mg/kg” and “XTMAB-16 4mg/kg”.
Its studies are mostly in Sarcoidosis, Pulmonary, led by Xentria.
Furthest: phase 2, since Nov 17, 20233 company-led studies, 1 open or runningNext primary completion: Oct 31, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xentria | 31 open or running | phase 2since Nov 17, 2023 | Jul 7, 2021 | Oct 31, 2029phase 2 · NCT07680166 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT04971395 · 25 enrolled · United States
- Nov 17, 2023Phase 2 study in Sarcoidosis, PulmonaryNCT06169397 · 31 enrolled · United States, Czechia, Poland and more
- Jun 25, 2026Phase 2 study in Sarcoidosis, PulmonaryNCT07680166 · 182 planned
Ahead
- Oct 31, 2029Primary completion: phase 2 study in Sarcoidosis, PulmonaryNCT07680166
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07680166Sarcoidosis, Pulmonary | 2 | Not yet recruiting | Oct 31, 2029 | 182 |
| NCT06169397Sarcoidosis, Pulmonary · United States, Czechia, Poland and more | 2 | Completed | Oct 9, 2026 | 31 |
| NCT04971395Healthy Participants · United States | 1 | Completed | Mar 18, 2022 | 25 |
How it is read
Names in the registry
- “XTMAB-16”, 2 entries
- “XTMAB-16 2 mg/kg”, 1 entry
- “XTMAB-16 4mg/kg”, 1 entry
Codes read as this program: XTMAB16.
Conditions, from the studies’ own filings
- Sarcoidosis, Pulmonary, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.